Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPARHT: Dapagliflozin for Renal Protection in Heart Transplant Recipients
2021-003175-34Phase 3Active
- Sponsor
- Oslo University Hospital
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of dapagliflozin in post-orthotopic heart transplantation status, chronic kidney disease (CKD) and diabetes mellitus (DM), sponsored by Oslo University Hospital. Primary endpoint: Slope of eGFR from 2 weeks to 12 months. Started Nov 2021; status: active.
02
Drugs
dapagliflozin
03
Conditions
post-orthotopic heart transplantation statuschronic kidney disease (CKD)diabetes mellitus (DM)
Beyond the preview
Go deeper on 2021-003175-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003175-34.